Trials / Unknown
UnknownNCT02688673
DC Vaccine Combined With CIK Cells in Patients With SCLC
Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Extensive-Stage Small- Cell Lung Cancer: a Phase I/II Study
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety and efficacy of dendritic cells (DC) combined with cytokine-induced killer (CIK) cells treatment patients with Extensive-Stage Small-Cell Lung Cancer. Experimental adopted recombinant adenovirus-code MUC1 and Survivin transfected DC, which are used for DC-based immunotherapy. Based on the results of our previously preclinical research with DC combined with CIK cells, the investigators plan to perform the clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adenovirus-transfected autologous DC vaccine plus CIK cells |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2016-08-01
- Completion
- 2016-11-01
- First posted
- 2016-02-23
- Last updated
- 2016-02-23
Source: ClinicalTrials.gov record NCT02688673. Inclusion in this directory is not an endorsement.